by Raynovich Rod | Jun 18, 2021 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-1 6/18 On a Risk-Off Day with Selling at Close NASDAQ down 0.92% to 14030, ARKG down 0.62%,IBB down 0.185, XBI down 0.6%, XLV down 1.14% at $123.74. iShares Medical Device ETF (IHI) down 0.65% at $350.67. Focus Mid-Cap Life Science Stocks: CYRX down 1.77% to...
by Raynovich Rod | Jun 11, 2021 | 2024 Rayno Biopharmaceuticals Portfolio
6/16 At close: Benign reaction from FED meeting. Maybe investors have accepted reality that low interest rates are not going to last forever and are less ebullient. Market needs a few days to digest Chairman Powell’s remarks. Rate hikes pushed out til 2023 but...
by Raynovich Rod | Jun 9, 2021 | 2024 Rayno Biopharmaceuticals Portfolio
Update 6/14 2p -EDT The ASCO Rally tailwind looks good whether you are a trader or long term investor. As we called it on May 31 we thought the timing was right to add positions to biotech stocks. The rally is a bit more spotty now after a ~10% + move in the XBI but...
by Raynovich Rod | May 31, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Healthcare stocks
Update-4 6/4 11 a EDT Finally small cap biotechs catch a rally: among my holdings: CRSP, EDIT, PACB, VCYT . ARKG and IBB up. But large caps look better today.FDA authorizes Regeneron subcutaneous dosage for COVID-10 antibody therapy. Update-3 6/3 after...
by Raynovich Rod | May 24, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 5/27…AstraZeneca (AZN) inched up to $56.89 leading the large caps today. Moderna (MRNA) rose 2.25% to $179 level close to its 52 week high of $189. VIR was a big loser down 5.59% to $43.20. Both the ARKG and the XBI are in a stable intermediate bottom...
by Raynovich Rod | May 18, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
May 20 The IBB was up over 2% and most biotechs were up. Momentum is expected to improve through July. We added to our bottom fishing on ARKG today at $78 level. Large caps perked up as well: BMY up 2.2%, AZN up 1,95%, RHHBY up 1.68%,LLY up 1.54%,...
by Raynovich Rod | May 9, 2021 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-3 11:20a 5/17. Large Caps continue to Look Good; Defensive with dividends and a little growth. ~1% movers as of mid-day trading: AZN, BIIB,GILD, GSK, REGN. IBB lags. Update-2 1:15p EDT Biotech stocks remain sluggish as NASDAQ rally slumps to red. Large caps...
by Raynovich Rod | Apr 30, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
5/7/21 10:30a EDT Nice Move in Regeneron (REGN). I finally made a good option trade . I wanted to own REGN which looks undervalued (PE about 12, P/S 6.30) among large cap biopharma. Q1 Results were good but concerns remain on Sanofi R&D relationship.The key to...
by Raynovich Rod | Apr 26, 2021 | Biopharmaceuticals, Clinical Diagnostics and Tools, vacciines
Biotech Week in Review 4/19-4/23 2021 Healthcare stocks led in an up and down week.XLV up 9% YTD. Major indices buffeted by potential capital-gains tax increases. Biopharma held recent bottom with gains for the week. It was a good week to take a vacation and hold our...
by Raynovich Rod | Apr 12, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 A Bit of a Rally despite the JNJ Vaccine Setback We have the best day for life science stocks in weeks despite a “pause” in distribution of the JNJ vaccine due to blood clots. Many experts don’t think it is a major problem just a...